Diabetic patient with arteriosclerosis and cholelithiasis treated by imeglimin (Twymeeg) and vildagliptin/metformin (EquMet)

Okada M, Bando H, Iwatsuki N, Ogawa T and Sakamoto K

Published on: 2023-09-01

Abstract

This case is 81-year-old male patient with type 2 diabetes (T2D), dyslipidemia, cerebral vascular accident (CVA), and cholelithiasis. His HbA1c increased to 8.8% in December 2022, and then oral hypoglycemic agents (OHAs) were changed to vildagliptin/metformin (EquMet) and imeglimin (Twymeeg). The add-on treatment was effective as HbA1c 6.6% in July 2023. By plethysmography for diabetic macroangiopathy, cardio-ankle vascular index (CAVI) showed for 10.3 to 12.1 with decreased ankle brachial index (ABI) as 0.72/0.88, indicating peripheral artery disease (PAD). International large studies for imeglimin showed effective add-on therapy by Trials of IMeglimin for Efficacy and Safety (TIMES) 1, 2 and 3.